## ADULT (≥18 YEARS OF AGE) GROWTH HORMONE PRIOR AUTHORIZATION REQUEST FORM



Today's Date

OptumRx
P.O. Box 25184
Santa Ana, CA, 92799
Phone: (800) 310-6826 Fax: (866) 940-7328





Note: This form must be completed by	the prescribing	provider.		
**All sections mu	st be complete	d or the request v	will be returned**	
Patient's Medicaid #		Date of Birth		
Patient's Name		Prescriber's Name		
Prescriber's IN License #		Specialty		
Prescriber's NPI#		Prescriber's Signature		
Return Fax #	-	Return Phone #		
Check box if requesting retro-active PA		Date(s) of service retro-active eligibili	·	
Note: Submit PA requests for retroactive claims eligibility timelines) with dates of service prior to ervice 30 calendar days or less and going forward.	30 calendar days			
Requested Medication and Strength	Do	sage	Treatment Duration	
SOMATROPIN AGENTS – Initial Authori	zation			
Please select one of the following:  Member is transitioning from pedia	tric growth horm	one therapy		
*Must meet all of the following*	and growar norm	ione merapy		
<ul> <li>Member has reached adul</li> </ul>	t height			
	ormone therapy	for at least 1 mon	th before re-evaluation of the need	
for continued therapy  • Prescriber has determined	that member w	ill experience grow	vth hormone deficiency into	
adulthood and would recei			-	
Please select one of the following:		·		
Request is for a preferred	agent			
☐ Request is for a non-prefer	red agent with a	a product-specific i	ndication:	
List indication:				
	lize a non-prefe	red agent over pre	eferred agent based on the following	
medical justification:				
<del></del>				

01.01.2024 Page 1

	*The fo	Biochemical ev select one of th Request is for a Request is for a List indication:	preferred agent non-preferred a	e required for applicable te	or diagnosis	rting the diagr	nosis 1:	
	*The fo	llowing docum Documentation	el syndrome (Zor entation will be supporting the c indicating patier	required for diagnosis of	short bowel	syndrome	-	e"
	*The fo	Ilowing docum chexia" Quantitative me BIA (bioelectric	iated wasting or entation will be easurement of le impedance ana of involuntary w initial approval	e required for an body mas lysis)	or diagnosis	x of "HIV- ass	gy X-ray absor	ptiometry) or
	Membe	r has tried and f	/HIV anti-retrovii ailed one of the t pinol □ Megestro	following (in	clude trial da	ate, dose, freq	uency, duratio	
expand l, testing	ling intra	cranial lesions o	iber attests that or tumors prior to ember does not erapy.	initiating gro	owth hormoi	ne therapy	Yes No	essary
Please	complet	e the following:						
	Curren	t:	height:		_(inches)	weight:		_(lbs)
	3 mont	hs prior:	height:		_(inches)	weight:		_(lbs)
	6 mont	hs prior:	height:		_(inches)	weight:		_(lbs)

01.01.2024 Page 2

SOMATROPIN	AGENTS – Rea	uthorization			
Please select	one of the follow	ving:			
Membe	r has previously	been transitioned fro	om pediatric growth h	ormone therapy	
Please	select one of the	e following:			
	Request is for a	preferred agent			
	Request is for a	non-preferred agen	t with a product-spec	ific indication:	
	List indication:	,			
	_	l like to utilize a nor	a-preferred agent over	r nreferred agent	based on the following
			i-preferred agent over	r preferred agent	based on the following
	medical justifica	uon.			
☐ Membe	r has a diagnosis	of adult growth hor	mone deficiency and	is continuing gro	wth hormone
	select one of the	_	•	0.0	
	Request is for a preferred agent				
			t with a product-spec	ific indication:	
	List indication:	non protonou agon	t with a product open	mo maroadom.	
	_	l liko to utilizo a nor	n professed agent aver	r professed agent	based on the following
			i-preferred agent over	i preferred agent	based on the following
	medical justifica	tion:			
Membe	r has a diagnosis	of short bowel syn	drome and is continui	ing to receive spe	cialized nutritional
	t (documentatio			9	
	•	• •	waating or aaabayia s	and is continuing	grouth hormone
	_	o or mrv-associated	wasting or cachexia a	and is continuing	growth normone
therapy					
•			roviral regimen:		
•			ease in total body wei	ght or lean body r	mass from treatment
	baseline (docui	mentation required	1)		
For ALL indica	ations* – Prescri	ber attests that they	have performed all n	necessary testing	to ensure there are no
		-	iating growth hormon		
oxparialing intre		r tarrioro prior to mit	idding growth hormon	o morapy — 10	0 🗀 110
I.			hereby attest tha	at I have perform	ed all necessary
testing to ens	ure that this me	mber does not hav	hereby attest tha re expanding intracr	ranial lesions or	tumors prior to
	th hormone the				
Prescriber Sig	nature:				
Please comple	te the following:				
Currer	nt:	height:	(inches)	weight:	(lbs)
3 mon	ths prior:	height:	(inches)	weight:	(lbs)
6 mon	ths prior:	height:	(inches)	weight:	(lbs)

01.01.2024 Page 3

SOGROYA (SOMAPACITAN) – Initial Authorization
Diagnosis of adult growth hormone deficiency ☐ Yes ☐ No *The following documentation will be required for diagnosis of "adult growth hormone deficiency"  • Biochemical evidence or other applicable testing supporting the diagnosis
Member is 18 years of age or older ☐ Yes ☐ No
Please select one of the following:  Trial and failure of ALL preferred somatropin products List products trialed:  Prescriber would like to utilize a Sogroya (somapacitan) over ALL preferred somatropin agents based on the following medical justification:
Prescriber attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy $\square$ Yes $\square$ No
I,hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors prior to initiating growth hormone therapy.
Prescriber Signature:
SOGROYA (SOMAPACITAN) – Reauthorization
Prescriber attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate $\Box$ Yes $\Box$ No
I,hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors prior to initiating growth hormone therapy.  Prescriber Signature:

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.

01.01.2024 Page 4